Codexis (CDXS) – Company Press Releases
-
Codexis to Report First Quarter 2024 Financial Results on May 2
-
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
-
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
-
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
-
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
-
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
-
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
-
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
-
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
-
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
-
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
-
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
-
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
-
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
-
Codexis Reports Third Quarter 2023 Financial Results
-
Codexis to Participate in Upcoming Healthcare Conferences
-
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
-
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
-
Codexis to Report Third Quarter 2023 Financial Results on November 2
-
Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
-
Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
-
Codexis to Participate in Cantor Global Healthcare Conference
-
Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease
-
Codexis Reports Second Quarter 2023 Financial Results
-
Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
-
Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
-
Codexis Announces New Employment Inducement Grants
-
Codexis to Participate in Jefferies Healthcare Conference
-
Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA
-
Codexis Announces New Employment Inducement Grants
-
Codexis Reports First Quarter 2023 Financial Results
-
Codexis to Report First Quarter 2023 Financial Results on May 4
-
Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA
-
Codexis Announces New Employment Inducement Grants
-
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
-
Codexis Announces New Employment Inducement Grants
-
Codexis to Participate in Cowen 43rd Annual Health Care Conference
-
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
-
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
-
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
-
Codexis Announces New Employment Inducement Grants
-
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
-
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
-
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
-
Codexis Provides Update on Prioritized Corporate Strategy
-
Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference
-
Codexis to Participate in Upcoming Healthcare Conferences
-
Codexis Reports Third Quarter 2022 Financial Results
-
Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
Back to CDXS Stock Lookup
